SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire ...
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...
Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major ...
Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...
The financial terms of the deal were not discosed. Aficamten is an investigational selective, small molecule cardiac myosin inhibitor for the potential treatment of patients with HCM. CORXEL ...
This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten ...
Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel ...
The adjustment follows an analysis comparing the launch of a similar drug by Bristol Myers Squibb (NYSE:BMY), Camzyos, with the anticipated launch trajectory of Cytokinetics' aficamten.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback